Health and wellness company Perrigo Company plc (NYSE; TASE: PRGO) reported on Monday that it has received US Food and Drug Administration tentative approval for the generic version of Finacea Foam(azelaic acid) 15%.
The company added that it had announced a patent litigation suit with Bayer AG for the Finacea Foam (azelaic acid) 15%.
In conjunction with the patent litigation suit, LEO Pharma A/S acquired Finacea Foam (azelaic acid) 15% from Bayer AG and then substituted for Bayer AG as the lead plaintiff in the patent litigation suit concerning the product.
For the 12 months ending January 2019, the annual market sales were approximately USD62m as measured by IQVIA.
Dr Reddy's Laboratories unveils Pregabalin Capsules in the US market
Baxter Wins US FDA Approval of Myxredlin, The First and Only Ready-To-Use Insulin for IV Infusion
Novadoz Pharmaceuticals awarded US FDA approval for generic Pregabalin capsules
Dr. Reddy's Laboratories Launches Ramelteon Tablets, in the US Market
US FDA approves first generic Lyrica for mutliple indications
Rising Pharmaceuticals launches and begins shipment of generic version of Lyrica in US